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ABSTRACT
Background: Patients who have received a
hematopoietic cell transplantation can develop
graft-versus-host disease (GVHD). The liver, the
gastrointestinal tract, and/or the skin can be
affected by GVHD. Chronic sclerotic-type
cutaneous GVHD can occur at sites of
repetitive skin friction.
Purpose: To describe isomorphic sclerotic-type
GVHD and review chronic GVHD appearing in
a cutaneous immunocompromised district.
Methods: The clinical features of a 74-year-old
man with mantle cell lymphoma who
developed chronic sclerotic-type cutaneous
GVHD localized to the waistband area—which
had been exposed to repetitive skin injury—
after a second hematopoietic cell
transplantation are reported. Using the
PubMed database, an extensive literature
search was performed on chronic GVHD.
Case report and review: The cutaneous
immunocompromised district is an area of
skin whose local effective immunity has been
altered, thereby permitting the development of
a dysimmune reaction, infection, or tumor at
the site. A cutaneous isomorphic response refers
to a disease-associated skin lesion occurring at
the site of physical injury that is
morphologically similar to the existing
condition. Cutaneous chronic GVHD can
occur at sites of repetitive skin trauma as an
isomorphic response. The patient developed
sclerotic-type GVHD in a cutaneous area that
had previously experienced repeated irritation,
friction, and pressure. Isomorphic sclerotic-type
GVHD—in either the waistband area or
brassiere area or both—has also been observed
in other patients. In addition, cutaneous
chronic GVHD has been described not only at
the location of a previous, unrelated, and
healed skin disease as an isotopic response, but
also at the cutaneous site of earlier exposure to
radiotherapy or ultraviolet radiation as an
isoradiotopic response.
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Conclusion: Sclerotic and nonsclerotic skin
lesions of chronic GVHD can occur not only
as an isomorphic response, but also as either an
isotopic response or an isoradiotopic response
in a cutaneous immunocompromised district.
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INTRODUCTION
Graft-versus-host disease (GVHD) may affect the
liver, gastrointestinal tract, and/or skin of patients
who have received a hematopoietic cell
transplantation [1]. Chronic sclerotic-type
cutaneous GVHD can occur at sites of repetitive
skin friction [2]. A man with isomorphic
cutaneous GVHD presenting as sclerotic-type skin
lesions on the waistband is described and chronic
GVHD of the skin appearing in a cutaneous
immunocompromised district is reviewed.
METHODS
Informed consent was obtained from the
patient for being included in the study. Using
the PubMed database, an extensive literature
search was performed for the following topics:
chronic cutaneous GVHD, isomorphic
response, isotopic response, isoradiotopic
response, and immunocompromised district.
The results of the search were used to secure
reports of chronic GVHD appearing in a
cutaneous immunocompromised district.
CASE REPORT
A 74-year-old man with a history of mantle cell
lymphoma had received two prior
hematopoietic cell transplants. The patient
experienced several weeks of asymptomatic,
yet progressive, stiffening of the skin on the
distal right extremity and lower abdomen. The
patient also noted that the skin on the lateral
lower chest and upper abdomen had a rippled
appearance.
The mantle cell lymphoma was diagnosed in
2005. In September 2008, the patient
underwent an autologous stem cell transplant
using BEAM (carmustine, etoposide, cytarabine,
and melphalan) as a conditioning regimen. The
patient achieved a complete remission.
The patient’s lymphoma relapsed in July
2009 and he participated in a clinical trial
receiving intranodal injections of an
immunotherapy Ad-ISF35 (immune
stimulating factor 35). The patient was
withdrawn from the study after injection #3
because of lack of clinical improvement. From
October 2009 to April 2010, the patient
completed six cycles of bendamustine and
rituximab. The patient achieved a complete
clinical response, but had residual inguinal
lymphadenopathy; subsequently, new nodes
were discovered.
The patient underwent an allogeneic
hematopoietic peripheral blood stem cell
transplant using a sex-matched unrelated
donor in May 2010; the conditioning regimen
was fludarabine, melphalan, and rituximab. The
patient engrafted without complications and
again achieved a complete remission. The
patient subsequently developed biopsy-
confirmed acute cutaneous GVHD that
resolved after treatment with topical
corticosteroids.
In early February 2013, the patient noted
that his right forearm and hand were becoming
stiff and indurated. Similarly, the area of his
abdomen that came in contact with the
waistband of his pants was becoming
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indurated. Also, the area of his lateral abdomen
above his waistband became rippled. The
observed changes continued to progress.
Cutaneous examination in late March 2013
showed the patient’s right forearm to be
hyperpigmented and indurated; similarly, his
dorsal hand was also firm and there was no
elasticity of the overlying skin (Fig. 1). The
patient’s lower abdomen, particularly the areas
that came in contact with the waistband of his
pants and belt, was smooth and
hyperpigmented with areas of erythema; in
addition, the lower abdomen had developed a
confluent morphea-like sclerotic dermal
induration (Figs. 2a, b, 3, 4). The skin of the
patient’s lateral lower chest and abdomen had a
‘‘cellulite’’ appearance (Figs. 2, 4).
Biopsy from the right forearm, the waistband
area, and the lateral upper abdomen all showed
similar findings: sclerotic and thickened
collagen in the reticular dermis. In the
waistband area, these changes were
predominantly in the mid reticular dermis;
there was also loss of the perieccrine fat and a
sparse lymphocytic superficial perivascular
infiltrate. In the forearm and the upper
abdomen, the sclerosis began in the deep
reticular and extended into the subcutaneous
fat; lymphoplasmacytic inflammation was
noted at the junction of the deep reticular
dermis and subcutaneous fat in the forearm,
and extravasated erythrocytes were observed in
the reticular dermis of the abdomen.
Fig. 1 Sclerotic-type chronic cutaneous graft-versus-host
disease presenting with ﬁrm induration and hyperpigmentation
of the extensor right forearm and dorsal hand
Fig. 2 Frontal (a) and right side (b) views of the lower
chest and abdomen demonstrating sclerotic-type chronic
cutaneous graft-versus-host disease. An isomorphic
response to the repetitive ‘trauma’ from the patient’s belt
and pants shows a hyperpigmented—with areas of
erythema—conﬂuent zone of morphea-like induration
involving the waistband area. The lateral areas of his
lower chest and upper abdomen have a rippled, cellulite-
like appearance
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Correlation of the clinical presentation and
pathology findings established the diagnosis of
chronic sclerotic-type cutaneous GVHD; the
localization of GVHD to the waistband area
demonstrates an isomorphic response to the
repetitive irritation, friction, and pressure from
the patient’s belt and pants. The patient was
treated with oral prednisone (initially at 10 mg
per day for 2 weeks, and tapered to 5 mg per day
and 2.5 mg per day for 2 weeks each) and
topical tacrolimus 0.1% gel twice daily.
Clinical improvement was observed, with the
dermal plaques becoming less firm.
DISCUSSION
GVHD of the skin has traditionally been
classified as either acute or chronic. The
appearance of signs and symptoms of GVHD
within the first 100 days after transplant is now
referred to as classical acute GVHD. More
recently, additional categories of late acute
GVHD have been adopted: persistent (in
which acute GVHD continues past day 100),
recurrent (in which acute GVHD has resolved
and then relapses), and late onset (in which
acute GVHD appears after day 100) [1]. Acute
GVHD can also occur as an overlap syndrome
with chronic GVHD in which features of both
can concurrently present.
Chronic GVHD includes sclerotic and
nonsclerotic (such as eczematous, exfoliative,
ichthyosiform, lichen planus-like,
papulosquamous, poikilodermatous, and
psoriasiform) skin lesions [1, 3–5]. To date, risk
factors influencing cutaneous chronic GVHD
have not been clearly elucidated. However,
proposed markers of sclerotic-type GVHD
include CD3 T-cell dose in the graft,
eosinophilia, positive antinuclear antibodies,
and antecedent nonsclerotic chronic GVHD
skin involvement [6]. Also, the use of reduced-
intensity conditioning regimens may result in
survival of recipient antigen-presenting cells
that could be associated with chronic GVHD.
Recently, total body irradiation—particularly
in individuals who received a reduced-intensity
conditioning regimen—has been proposed as
an important risk factor for the subsequent
Fig. 3 Isomorphic sclerotic-type chronic cutaneous graft-
versus-host disease. The closer view shows the extensive
linear skin ﬁbrosis in the right lower abdomen waistband
area
Fig. 4 A closer view of the sclerotic involvement of
subcutaneous fat presenting with a rippled or ‘cellulite’
appearance of the skin in a patient with sclerotic-type
chronic cutaneous graft-versus-host disease. Fibrosis of the
skin in the waistband area demonstrating the patient’s
isomorphic sclerotic-type chronic cutaneous graft-versus-
host disease can also be seen on the lower abdomen
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development of sclerotic-type GVHD [6].
Specific mechanisms that may account for
sclerotic-type GVHD after total body
irradiation include: (1) type I interferon
(alpha/beta); (2) that radiotherapy produced
elevated interferon gamma (which along with
interferon-inducible chemokines is up regulated
in sclerotic-type GVHD skin); and (3)
promotion and maintaining of T-cell
cytotoxicity secondary to local production of
interferon and downstream factors. Also,
nonspecific radiation effects may predispose
patients to develop chronic GVHD; these
include damage to keratinocytes, depletion of
local immune regulatory factors, and
stimulation of systemic cytokine production
[6].
The immunocompromised district was
introduced by Rucco et al. [7] to describe the
occurrence of either dysimmune reactions,
infections, or tumors in an area of skin
that has been selectively damaged and
immunologically marked as the result of
either a reduction or induction of local
effective immunity. Conceptually, the
immunocompromised district unifies three
types of skin responses: isomorphic, isotopic,
and isoradiotopic [8].
The appearance of a skin lesion at the site
of physical trauma or injury that is
morphologically similar to an existing disease
was originally presented by Koebner in 1872
with regard to psoriasis [9]. However, the
Koebner phenomenon occurring at a localized
area with diminished resistance to disease—a
‘locus minoris resistentia’—has subsequently
been observed to occur in several diseases [10].
In this setting, it has also been referred to as the
isomorphic response [11].
Wolf’s isotopic response, originally described
in 1995, most commonly is associated with a
herpetic infection. It refers to the development
of a new cutaneous condition at the location of
a previous, unrelated, and already healed skin
disease [12]. In contrast, when the source of
injury to the skin is ionizing radiotherapy (or
subsequently expanded to also include
conventional electron beam radiotherapy and
ultraviolet radiation), the subsequent
isomorphic phenomenon has been referred to
as an isoradiotopic response [11, 13].
In addition to the patient in the present
report who developed GVHD localized to areas
of skin friction from the waistband of his pants,
isomorphic chronic cutaneous GVDH has also
been described in several patients with sclerotic-
type GVHD skin lesions. The patients include
other men with waistband-associated chronic
GVHD and women with brassiere band and/or
waistband-related chronic GVHD [1, 2, 11, 14];
of note, similar to the reported patient with
isomorphic (waistband) and idiopathic (right
forearm and hand) sclerotic-type GVHD, other
individuals with concurrent isomorphic
chronic cutaneous GVHD and idiopathic
sclerotic-type GVHD have been observed [11].
The source of injury associated with isomorphic
sclerotic-type GVHD has also been the sites of
injections of subcutaneous interferon alpha on
the abdomen [15], previous subclavian or
central venous catheter placement without
[14] or with [11] subsequent cellulitis, repeated
needle sticks to obtain blood from the right
antecubital fossa [11], suction blisters [16], and
Bacillus Calmette Guerin therapy [16]. In
addition, chronic GVHD with sclerotic-type
skin lesions has been observed to occur at the
healed sites of prior acute GVHD [16, 17].
Albeit rare, isomorphic nonsclerotic-type
chronic GVHD has also been observed. If, as
suggested by Girault et al. [18], striae distensae
are accepted to represent traumatized dermal
zones, then the lichenoid eruption of chronic
GVHD that were observed would be an
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isomorphic response. Clinically, the skin lesions
presented as finely squamous, atrophic
erythematous plaques in the striae distensae of
a 23-year-old man who received a bone marrow
transplant for acute leukemia at the age of 18;
microscopically, the lesions showed a
superficial lichenoid dermatitis [18].
Isotopic sclerotic-type and lichen planus-like
chronic GVHD have both been reported in
hematopoietic cell transplantation patients
most commonly localized to the sites of prior
varicella zoster virus infection [11, 16, 17,
19–23]. Dermatomal lichen planus-like chronic
GVHD has also been observed in transplant
patients who do not have a prior history of
varicella zoster virus infection [24, 25]; it has
been postulated that a subclinical viral infection
may explain their distinctive presentation of
chronic cutaneous GVHD [4].
Sclerotic-type GVHD has also occurred at the
site of prior measles virus exanthema. A 14-year-
old girl received an allogeneic bone marrow
transplant for aplastic anemia. The patient
developed measles 7 months post-transplant
and the viral exanthema resolved over
3 weeks. However, within the next 2 months,
poikiloderma and sclerotic-type chronic GVHD
appeared in the same areas as her acute measles
viral exanthem [26].
Sclerotic-type chronic GVHD within radiation
ports of four patients was described by Socie et al.
[27] in 1989. It was also reported more recently by
Martires et al. [11] to occur on the left distal femur
in a 58-year-old man with B-cell lymphoma who
received electron beam radiotherapy to this
location 4 months prior to an allogeneic
peripheral blood hematopoietic cell transplant.
Isoradiotopic sclerotic-type chronic GVHD also
occurred following ultraviolet radiation from
incidental sun exposure in a 51-year-old man
with multiple myeloma following allogeneic stem
cell transplant (which was preceded by an
autologous peripheral blood stem cell
transplant) [28]. Acute GVHD and nonsclerotic-
type GVHD have also been described following
either radiotherapy, narrow band ultraviolet B, or
incidental sun exposure [27–29].
Recently, Martires et al. [11] described a 60-
year-old man with both isomorphic and isotopic
chronic sclerotic-type GVHD. The patient had
received an allogeneic peripheral blood
hematopoietic cell transplantation for treatment
of B-cell lymphoma and developed a varicella
zoster virus infection on the T9–T10 dermatomes
of his left flank 8 months later. The patient
subsequently developed sclerotic-type GVHD
not only in the waistband areas (isomorphic
response) but also in the healed varicella zoster
virus infection scars (isotrophic response) 3 and
3.5 years after transplant, respectively [11]. Also,
similar to the present patient with a cellulite-
appearing abdomen, Martires et al’s patient also
had subcutaneous chronic GVHD involvement
characterized by cutaneous rippling of the skin on
both upper extremities [11].
CONCLUSION
The cutaneous immunocompromised district is
an area of skin whose local effective immunity
has been altered, thereby permitting the
development of a dysimmune reaction,
infection, or tumor at the site. A cutaneous
isomorphic response refers to a disease-
associated skin lesion occurring at the site of
physical injury that is morphologically similar
to the existing condition. A cutaneous isotopic
response refers to the development of a new
skin condition at the location of a previous,
unrelated, and healed skin disease. An
isoradiotopic response refers to a new skin
disease appearing at the cutaneous site of
earlier exposure to radiotherapy or ultraviolet
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radiation. Cutaneous chronic GVHD can occur
with sclerotic or nonsclerotic skin lesions. The
present patient developed chronic sclerotic-
type cutaneous GVHD localized to the
waistband area—which had been exposed to
repetitive skin injury—after his second
hematopoietic cell transplantation. Similar to
this patient, isomorphic sclerotic-type GVHD
in either the waistband area or brassiere area, or
both, has also been observed in other patients
with localized and repeated skin trauma (such
as irritation, friction, and pressure) to their
skin. In summary, sclerotic and nonsclerotic
skin lesions of chronic GVHD not only occur as
an isomorphic response, but also can develop
as an isotopic response or an isoradiotopic
response in a cutaneous immunocompromised
district.
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